Schizophrenia Overview

Principles

Definition

Schizophrenia is a complex neuropsychiatric disorder investigated as a major academic and research concept across psychiatry, neuroscience, genetics, and psychology. Research in this field focuses on understanding its etiology, pathophysiology, varied clinical manifestations (including psychosis, disorganized thinking, and negative symptoms), diagnosis, and treatment, representing a critical area of inquiry due to its significant public health impact and the insights it offers into severe brain dysfunction.

Ontological type

Treatment strategies

Etiological factors

Neurobiological mechanisms

Key developments

Key Figures

Biological-Genetic Foundations era

Irving I. Gottesman [1] was a central figure in this era, with affiliations at the University of Minnesota [3] and the University of North Carolina at Chapel Hill [4]. His 1967 paper A polygenic theory of schizophrenia [7] proposed that multiple genes contribute to risk, reframing biological-genetic inquiry in psychiatry. Peter J. Lang [2] was another pivotal figure, with affiliations at the University of Wisconsin–Madison [5] and the University of Pittsburgh [6] during this era. His 1965 paper Psychological deficit in schizophrenia: II. Interference and activation [8] examined cognitive processing and activation deficits, underscoring neuropsychological dimensions that shaped biological-genetic research then.

Neurochemical-to-Circuit Shift era

Nancy C. Andreasen [1] is a central figure in the Neurochemical-to-Circuit Shift era, with ties to Harvard University [3] and Washington University in St. Louis [4]. Her work on Negative Symptoms in Schizophrenia [6], Negative v Positive Schizophrenia [7], and Structural Abnormalities in the Frontal System in Schizophrenia [8] articulated a move toward frontal-subcortical dysfunction, linking symptom dimensions to emerging neurochemical and circuit theories that shaped research priorities of the era. Daniel R. Weinberger [2] is a parallel figure, with affiliations at Harvard University [3] and the University of Maryland, Baltimore [5]. His papers Implications of Normal Brain Development for the Pathogenesis of Schizophrenia [9] and Cerebral Ventricular Enlargement in Chronic Schizophrenia [10] connected developmental and structural brain changes to neurochemical models, reinforcing the shift from neurotransmitter hypotheses to circuit-based frameworks that defined diagnostic and therapeutic thinking in this era.

Polygenic Immune-Circuit Integration era

Patrick F. Sullivan [1] is a prominent figure associated with Harvard University [3] and the University of California, San Francisco [4] during the Polygenic Immune-Circuit Integration era. His work, including the 2009 paper 'Common polygenic variation contributes to risk of schizophrenia and bipolar disorder' [7] and the 2013 study 'Genome-wide association analysis identifies 13 new risk loci for schizophrenia' [8], helped establish that common polygenic variation shapes schizophrenia risk and that discovering multiple loci clarifies the polygenic architecture underlying disease. Michael Gill [2] is associated with The University of Texas Southwestern Medical Center [5] and The University of Texas Health Science Center at San Antonio [6] during this era. His key contributions include the 2009 paper 'Common polygenic variation contributes to risk of schizophrenia and bipolar disorder' [7] and the 2013 study 'Genome-wide association analysis identifies 13 new risk loci for schizophrenia' [8], which advanced the view that polygenic risk and multiple loci inform the neural circuitry and immune components involved in schizophrenia.